MX2022002607A - Metodos de tratamiento. - Google Patents
Metodos de tratamiento.Info
- Publication number
- MX2022002607A MX2022002607A MX2022002607A MX2022002607A MX2022002607A MX 2022002607 A MX2022002607 A MX 2022002607A MX 2022002607 A MX2022002607 A MX 2022002607A MX 2022002607 A MX2022002607 A MX 2022002607A MX 2022002607 A MX2022002607 A MX 2022002607A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- pde1
- tumors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La divulgación se relaciona con la combinación de inhibidores de fosfodiesterasa 1 (PDE1) útil para el tratamiento de determinados cánceres o tumores, como el cáncer de colon. En otra modalidad, la divulgación se relaciona al uso de inhibidores de PDE1 y un agente antitumoral opcional para el tratamiento de ciertos cánceres o tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962895476P | 2019-09-03 | 2019-09-03 | |
PCT/US2020/049248 WO2021046250A1 (en) | 2019-09-03 | 2020-09-03 | Methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002607A true MX2022002607A (es) | 2022-03-25 |
Family
ID=74853030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002607A MX2022002607A (es) | 2019-09-03 | 2020-09-03 | Metodos de tratamiento. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220354851A1 (es) |
EP (1) | EP4025218A4 (es) |
JP (1) | JP2022546711A (es) |
KR (1) | KR20220054853A (es) |
CN (1) | CN114340636A (es) |
AU (1) | AU2020343329A1 (es) |
BR (1) | BR112022003670A2 (es) |
CA (1) | CA3147071A1 (es) |
IL (1) | IL290983A (es) |
MX (1) | MX2022002607A (es) |
WO (1) | WO2021046250A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6810613B2 (ja) * | 2014-06-20 | 2021-01-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
JP6596080B2 (ja) * | 2014-09-17 | 2019-10-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 化合物および方法 |
RU2753543C1 (ru) * | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
WO2019046778A1 (en) * | 2017-08-31 | 2019-03-07 | Mavupharma, Inc. | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP-1) AND USES THEREOF |
EP3908285A4 (en) * | 2019-01-07 | 2022-10-19 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
-
2020
- 2020-09-03 BR BR112022003670A patent/BR112022003670A2/pt unknown
- 2020-09-03 WO PCT/US2020/049248 patent/WO2021046250A1/en active Application Filing
- 2020-09-03 CN CN202080062144.3A patent/CN114340636A/zh active Pending
- 2020-09-03 KR KR1020227010604A patent/KR20220054853A/ko unknown
- 2020-09-03 CA CA3147071A patent/CA3147071A1/en active Pending
- 2020-09-03 JP JP2022514215A patent/JP2022546711A/ja active Pending
- 2020-09-03 AU AU2020343329A patent/AU2020343329A1/en active Pending
- 2020-09-03 EP EP20860677.2A patent/EP4025218A4/en active Pending
- 2020-09-03 MX MX2022002607A patent/MX2022002607A/es unknown
- 2020-09-03 US US17/640,050 patent/US20220354851A1/en active Pending
-
2022
- 2022-02-28 IL IL290983A patent/IL290983A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021046250A1 (en) | 2021-03-11 |
JP2022546711A (ja) | 2022-11-07 |
CN114340636A (zh) | 2022-04-12 |
EP4025218A4 (en) | 2023-05-31 |
US20220354851A1 (en) | 2022-11-10 |
BR112022003670A2 (pt) | 2022-05-24 |
CA3147071A1 (en) | 2021-03-11 |
AU2020343329A1 (en) | 2022-03-24 |
EP4025218A1 (en) | 2022-07-13 |
IL290983A (en) | 2022-05-01 |
KR20220054853A (ko) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018265888A1 (en) | Use of anti-B7H3 antibodies for treating cancer in the central nervous system | |
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
MX2022007678A (es) | Compuestos y metodos para la degradacion dirigida del receptor de androgenos. | |
MX2017014735A (es) | Metilacion de promotor pd-l1 en cancer. | |
MXPA05013822A (es) | Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer. | |
EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
AU2015314007B2 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
AU2018380132A8 (en) | Tubulin inhibitors | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
MX2023011608A (es) | Metodos para inhibir ras. | |
WO2019023315A3 (en) | RAC INHIBITORS | |
PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
MX2021009514A (es) | Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon. | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
MX2023013912A (es) | Metodos para inhibir ras. | |
PH12021550376A1 (en) | Combination therapy | |
PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |